Encephalomyelitis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Encephalomyelitis - Pipeline Review, H1 2016', provides an overview of the Encephalomyelitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Encephalomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Encephalomyelitis - The report reviews pipeline therapeutics for Encephalomyelitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Encephalomyelitis therapeutics and enlists all their major and minor projects - The report assesses Encephalomyelitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Encephalomyelitis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Encephalomyelitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Encephalomyelitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Encephalomyelitis Overview 6 Therapeutics Development 7 Pipeline Products for Encephalomyelitis - Overview 7 Pipeline Products for Encephalomyelitis - Comparative Analysis 8 Encephalomyelitis - Therapeutics under Development by Companies 9 Encephalomyelitis - Therapeutics under Investigation by Universities/Institutes 10 Encephalomyelitis - Pipeline Products Glance 11 Early Stage Products 11 Encephalomyelitis - Products under Development by Companies 12 Encephalomyelitis - Products under Investigation by Universities/Institutes 13 Encephalomyelitis - Companies Involved in Therapeutics Development 14 Bionure Farma, S.L. 14 Biovista Inc. 15 Effimune SAS 16 InteKrin Therapeutics, Inc. 17 Merck & Co., Inc. 18 Momenta Pharmaceuticals, Inc. 19 Encephalomyelitis - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 Antibody for Autoimmune Disorders and Inflammation - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 BN-201 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 FR-104 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 INT-131 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 JM-4 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 PSA-20 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 SCH-546738 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecule for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 thymulin - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 WEHI-345 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Encephalomyelitis - Recent Pipeline Updates 41 Encephalomyelitis - Dormant Projects 44 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 46 Disclaimer 47
List of Tables
Number of Products under Development for Encephalomyelitis, H1 2016 7 Number of Products under Development for Encephalomyelitis - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Products under Investigation by Universities/Institutes, H1 2016 13 Encephalomyelitis - Pipeline by Bionure Farma, S.L., H1 2016 14 Encephalomyelitis - Pipeline by Biovista Inc., H1 2016 15 Encephalomyelitis - Pipeline by Effimune SAS, H1 2016 16 Encephalomyelitis - Pipeline by InteKrin Therapeutics, Inc., H1 2016 17 Encephalomyelitis - Pipeline by Merck & Co., Inc., H1 2016 18 Encephalomyelitis - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 28 Encephalomyelitis Therapeutics - Recent Pipeline Updates, H1 2016 41 Encephalomyelitis - Dormant Projects, H1 2016 44 Encephalomyelitis - Dormant Projects (Contd..1), H1 2016 45
List of Figures
Number of Products under Development for Encephalomyelitis, H1 2016 7 Number of Products under Development for Encephalomyelitis - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Targets, H1 2016 21 Number of Products by Stage and Targets, H1 2016 21 Number of Products by Mechanism of Actions, H1 2016 23 Number of Products by Stage and Mechanism of Actions, H1 2016 23 Number of Products by Routes of Administration, H1 2016 25 Number of Products by Stage and Routes of Administration, H1 2016 25 Number of Products by Molecule Types, H1 2016 27 Number of Products by Stage and Molecule Types, H1 2016 27
Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from mainRead More...
Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commercRead More...
Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehiRead More...
Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certainRead More...
Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecastRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.